Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Codexis, Inc. (CDXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Codexis is listed on The Nasdaq Global Select Market, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934, as reflected in its Form 8-K filings. These filings give investors insight into how Codexis reports its financial condition, strategic actions and material events related to its enzymatic solutions for therapeutics manufacturing and its ECO Synthesis® / ECO Synthesis™ platform.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which typically contain detailed discussions of Codexis’s business, risk factors, financial statements and management’s analysis of results. For a company focused on enzyme technologies and oligonucleotide manufacturing, these filings can shed light on revenue contributions from its Pharma Biocatalysis business, investments in research and development for platforms such as CodeEvolver® and ECO Synthesis, and the financial impact of collaborations and licensing arrangements.
Codexis also files Form 8-K current reports to disclose material events. For example, an 8-K dated November 6, 2025 reports quarterly financial results and describes a workforce reduction aligned with an enhanced strategic focus on the ECO Synthesis platform, as well as executive leadership changes. Another 8-K dated August 13, 2025 announces financial results for the quarter ended June 30, 2025. These current reports help investors track significant developments between periodic filings.
On this page, users can also review Form 4 insider transaction reports and other relevant filings, where available, to understand equity awards and trading activity by directors and officers. Stock Titan enhances access to these documents with AI-powered summaries that explain key points from lengthy filings, highlight important sections in 10-K and 10-Q reports, and clarify the implications of 8-K disclosures. Real-time updates from EDGAR ensure that new Codexis filings, including those related to its enzyme-based manufacturing initiatives and organizational changes, are reflected promptly for further review and analysis.
Codexis, Inc. filed a current report to disclose that it has announced its financial results for the quarter ended June 30, 2025. The company released these results through a press release dated August 13, 2025, which is furnished as Exhibit 99.1. This press release contains the detailed quarterly financial information. The exhibit is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities offerings unless specifically referenced.
Aberdeen Group plc and its U.S. affiliate abrdn Inc. jointly filed a Schedule 13G reporting passive ownership of 4,200,950 Codexis (CDXS) common shares as of 30 Jun 2025. The position equals 5.07 % of outstanding stock, making the firms a 5-percent beneficial owner under SEC rules.
The filing states shared voting and dispositive power over the entire stake; neither entity holds sole authority. Aberdeen is classified as a parent holding company/control person (HC) incorporated in the United Kingdom, while abrdn Inc. is a U.S. corporation and registered investment adviser (CO, IA). Both certify the shares were acquired in the ordinary course of business and not to influence control of Codexis.
Signatures were provided by Major Shareholding Reporting Analyst Jenny Clarke on 30 Jul 2025. No exhibits indicate activist intent, group formation, or additional derivatives. The disclosure primarily informs investors of a new institutional holder exceeding the 5 % threshold, adding visibility to Codexis’ shareholder base without signaling governance changes.